• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在以西班牙裔为主的人群中的患病率及耐药情况

Prevalence and resistance of in a predominantly Hispanic population.

作者信息

Tabesh Alireza, Antillon Ricardo Alberto, Kondradzhyan Manvel, Tan Ann Zera

机构信息

Internal Medicine, Adventist Health White Memorial, Los Angeles, CA 90033, United States.

Family Medicine, UCLA, Los Angeles, CA 90024, United States.

出版信息

World J Gastrointest Endosc. 2024 Sep 16;16(9):526-532. doi: 10.4253/wjge.v16.i9.526.

DOI:10.4253/wjge.v16.i9.526
PMID:39351177
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11438584/
Abstract

BACKGROUND

() is the most common chronic bacterial infection in humans. The risk of acquiring is related to socioeconomic status and living conditions early in life. Treatment regimens must consider local antibiotic resistance patterns. Adventist Health White Memorial Hospital serves a predominantly indigent population in east Los Angeles with a large number of immigrants from South and Central America. Data regarding the prevalence and resistance of in this population is scant.

AIM

To evaluate the prevalence and resistance of and correlate with country of origin.

METHODS

All gastric biopsies were obtained by a single gastroenterologist at the hospital in a consecutive manner from patients with gastritis from 2017 to 2022 and sent to various labs for evaluation.

RESULTS

Two hundred and sixty-six patients are born in the United States, 450, 171, 70, and 30 patients are immigrants from Mexico, Central and South America (CSA), Asia, and other countries respectively. Overall, 14.65% were found to be infected with . Rates of infection in United States-born citizens, immigrants from Mexico, CSA, and Asia are 9.02%, 18.67%, 13.45%, and 11.43% respectively, with Mexican immigrants having a relative risk of 2.3889 [95% confidence interval (CI): 1.4789-3.8588, = 0.0004] compared to those born in United States. No correlation seen between infection and length of time immigrants were in United States. Relative risk of infection in patients with no proton pump inhibitor use within the past 30 days found to be 1.9276 (95%CI: 1.3562-2.7398, = 0.0003). Rates of resistance for clarithromycin and levofloxacin are 21.43% and 31.11%.

CONCLUSION

infection appears to be associated with low socioeconomic status and poor living conditions early in life. Clarithromycin and levofloxacin based treatment regimens should be avoided as first line therapy in this region, particularly in patients of Latin American origin.

摘要

背景

(某种细菌)是人类最常见的慢性细菌感染。感染该细菌的风险与社会经济地位和早年生活条件有关。治疗方案必须考虑当地的抗生素耐药模式。复临健康白纪念医院主要服务于洛杉矶东部的贫困人口,其中有大量来自南美洲和中美洲的移民。关于该人群中该细菌的流行率和耐药性的数据很少。

目的

评估该细菌的流行率和耐药性,并与原籍国相关联。

方法

2017年至2022年期间,由医院的一名胃肠病学家连续从胃炎患者中获取所有胃活检样本,并送往不同实验室进行评估。

结果

266名患者出生在美国,450名、171名、70名和30名患者分别是来自墨西哥、中南美洲(CSA)、亚洲和其他国家的移民。总体而言,发现14.65%的人感染了该细菌。美国出生的公民、来自墨西哥、CSA和亚洲的移民的感染率分别为9.02%、18.67%、13.45%和11.43%,与在美国出生的人相比,墨西哥移民的相对风险为2.3889[95%置信区间(CI):1.4789 - 3.8588,P = 0.0004]。未发现感染与移民在美国的时间长短之间存在相关性。在过去30天内未使用质子泵抑制剂的患者中,感染的相对风险为1.9276(95%CI:1.3562 - 2.7398,P = 0.0003)。克拉霉素和左氧氟沙星的耐药率分别为21.43%和31.11%。

结论

该细菌感染似乎与早年社会经济地位低和生活条件差有关。在该地区,应避免将基于克拉霉素和左氧氟沙星的治疗方案作为一线治疗,特别是对于拉丁裔患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92e2/11438584/0cfdace9143a/WJGE-16-526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92e2/11438584/0cfdace9143a/WJGE-16-526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92e2/11438584/0cfdace9143a/WJGE-16-526-g001.jpg

相似文献

1
Prevalence and resistance of in a predominantly Hispanic population.在以西班牙裔为主的人群中的患病率及耐药情况
World J Gastrointest Endosc. 2024 Sep 16;16(9):526-532. doi: 10.4253/wjge.v16.i9.526.
2
High rates of clarithromycin and levofloxacin resistance of Helicobacter pylori in patients with chronic gastritis in the south east area of Vietnam.越南东南部地区慢性胃炎患者幽门螺杆菌克拉霉素和左氧氟沙星耐药率较高。
J Glob Antimicrob Resist. 2020 Sep;22:620-624. doi: 10.1016/j.jgar.2020.06.007. Epub 2020 Jun 24.
3
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症,原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
4
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.亚太地区幽门螺杆菌的主要抗生素耐药性:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):707-715. doi: 10.1016/S2468-1253(17)30219-4. Epub 2017 Aug 7.
5
Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial.墨西哥采用基于左氧氟沙星的方案与标准三联疗法根除幽门螺杆菌:一项开放标签、随机、非劣效性 IIIb 期试验的结果
Rev Gastroenterol Mex (Engl Ed). 2019 Jul-Sep;84(3):274-283. doi: 10.1016/j.rgmx.2018.04.005. Epub 2018 Jul 27.
6
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?基于左氧氟沙星或克拉霉素的四联疗法:在两种抗生素耐药率都很高的国家,作为根除幽门螺杆菌的一线治疗,哪种是最佳替代方案?
BMC Gastroenterol. 2017 Feb 15;17(1):31. doi: 10.1186/s12876-017-0589-6.
7
Analysis of Helicobacter pylori resistance in patients with different gastric diseases.分析不同胃部疾病患者的幽门螺杆菌耐药性。
Sci Rep. 2024 Feb 28;14(1):4912. doi: 10.1038/s41598-024-55589-2.
8
Eradication Rate of on the US-Mexico Border Using the Urea Breath Test.使用尿素呼气试验检测美墨边境地区的根除率。
South Med J. 2018 Jan;111(1):51-55. doi: 10.14423/SMJ.0000000000000747.
9
Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.意大利东北部幽门螺杆菌对抗生素的耐药性:一项多中心研究。GISU。溃疡研究跨学科小组。
Dig Liver Dis. 2000 Dec;32(9):763-8. doi: 10.1016/s1590-8658(00)80352-7.
10
Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.含克拉霉素和左氧氟沙星方案治疗既往新冠治疗患者的幽门螺杆菌根除率:一项随机临床试验。
BMC Infect Dis. 2023 Jan 20;23(1):36. doi: 10.1186/s12879-023-07993-8.

引用本文的文献

1
Decoding the Ability of Helicobacter pylori to Evade Immune Recognition and Cause Disease.解析幽门螺杆菌逃避免疫识别并引发疾病的能力。
Cell Mol Gastroenterol Hepatol. 2025;19(5):101470. doi: 10.1016/j.jcmgh.2025.101470. Epub 2025 Jan 30.
2
Prevalence of intestinal parasites and Helicobacter pylori co-infection in people with gastrointestinal symptoms in Africa: a systematic review and meta-analysis.非洲有胃肠道症状人群中肠道寄生虫与幽门螺杆菌合并感染的患病率:一项系统评价与荟萃分析
BMC Infect Dis. 2025 Jan 3;25(1):20. doi: 10.1186/s12879-024-10432-x.

本文引用的文献

1
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe.幽门螺杆菌分离株的抗生素耐药率在美国和欧洲的临床试验患者中。
Am J Gastroenterol. 2023 Feb 1;118(2):269-275. doi: 10.14309/ajg.0000000000002045. Epub 2022 Sep 30.
2
National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial.美国全国及地区幽门螺杆菌抗生素耐药性:来自一项临床试验的经验教训。
Gastroenterology. 2021 Jul;161(1):342-344.e1. doi: 10.1053/j.gastro.2021.03.045. Epub 2021 Mar 31.
3
Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment.
毒力因子-胃微环境中细菌致病性的机制。
Cells. 2020 Dec 25;10(1):27. doi: 10.3390/cells10010027.
4
Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model.墨西哥幽门螺杆菌感染的感染力:使用分层贝叶斯模型进行全国调查的证据。
Epidemiol Infect. 2018 Jun;146(8):961-969. doi: 10.1017/S0950268818000857. Epub 2018 Apr 16.
5
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.全球幽门螺杆菌感染率:系统评价和荟萃分析。
Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27.
6
Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models.幽门螺杆菌诱导的胃部病理学:体内和体外模型的见解
Dis Model Mech. 2017 Feb 1;10(2):89-104. doi: 10.1242/dmm.027649.
7
Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.幽门螺杆菌抗生素耐药性的流行情况:近期文献综述
World J Methodol. 2015 Sep 26;5(3):164-74. doi: 10.5662/wjm.v5.i3.164.
8
The antibiotic resistance crisis: part 1: causes and threats.抗生素耐药性危机:第一部分:成因与威胁。
P T. 2015 Apr;40(4):277-83.
9
The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.幽门螺杆菌对抗生素耐药性的问题:拉丁美洲的系统评价。
Am J Gastroenterol. 2014 Apr;109(4):485-95. doi: 10.1038/ajg.2014.24. Epub 2014 Mar 4.
10
Helicobacter pylori treatment in the era of increasing antibiotic resistance.幽门螺杆菌在抗生素耐药时代的治疗。
Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4.